GlobeNewswire All Public CompaniesQwen · 实盘不做把握 9/10不做原因:不是事件🔁 +1 同一事件
北京时间·🕒 发布 20:30:00·⟳ 抓取 20:32:38·⚡ 决策 08-31 20:34:08 +1m30s·57.1 天前
Allogene Therapeutics宣布将参加9月9日Citi Biopharma Back to School投资者会议
该公告为标准的投资者会议参与日程通知，不含任何新增实质性事实（无临床数据读出、无监管决定、无合作协议、无财务指引变化、无产品进展）。此类公告对股价无因果传导机制，不构成可交易催化。
📄 原文GlobeNewswire All Public Companies↗ 原文
Allogene Therapeutics Announces Participation in September Investor Conference
SOUTH SAN FRANCISCO, Calif., Aug. 31, 2026 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-s…
不做 Allogene Therapeutics（ALLO.US）
纯日程性投资者会议参与公告，不含任何新增实质性信息（无数据、无审批、无合作、无指引），对股价无因果传导，不构成可交易催化
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
结论摘要
Allogene Therapeutics于2026年8月31日通过GlobeNewswire发布新闻稿，宣布将于9月9日参加Citi Biopharma Back to School投资者会议。全文仅包含会议时间、webcast链接和公司标准简介/前瞻性声明，无任何新临床数据、监管里程碑、商业合作或财务指引。这是上市公司常规IR沟通，市场对此类公告无价格反应预期，不构成交易机会。
🔎 新鲜度:最早出现 2026-08-31 · 扩散 low · price-in 风险 low ↗
先例如何影响了这次决策
对本次决策的影响:无需先例即可判定：此类公告在学术文献和实证中均无统计显著的价格影响
方向:不适用——会议参与公告无历史价格反应先例可循
涨幅量级:不适用
形态:不适用
工具执行结果 · 成功 1 · 降级 0 · 失败 0 · 取消 0
- search_processed_events 成功 stock_tools HTTP · 7,261 ms
{"result": "search_processed_events:agent query=`allo citi biopharma conference participation | allogene therapeutics investor conference`；结构化索引覆盖完整 72 小时；旧记录兼容扫描近 71.3/72 小时、1070 条本臂决策(完整)，返回 0 条候选。未命中只表示这些 agent query 表达式没有召回候选，不能据此证明消息首发或不是重复；按当前事件继续正常研判。"}
原文全文
展开原文 · 3,105 字
SOUTH SAN FRANCISCO, Calif., Aug. 31, 2026 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T) products for cancer and autoimmune disease, today announced that it will participate in the following upcoming investor conference in September.
Citi Biopharma Back to School Conference
Wednesday, September 9
5:00 a.m. PT/8:00 a.m. ET
Any available webcasts will be posted to the Company’s website at
www.allogene.com
under the Investors tab in the News and Events section. Following a live webcast, a replay will be available on the Company’s website for approximately 30 days.
About Allogene Therapeutics
Allogene Therapeutics, with headquarters in South San Francisco, is a clinical-stage biotechnology company pioneering the development of allogeneic chimeric antigen receptor T cell (AlloCAR T) products for cancer and autoimmune disease. Led by a management team with significant experience in cell therapy, Allogene is developing a pipeline of off-the-shelf CAR T cell product candidates with the goal of delivering readily available cell therapy on-demand, more reliably, and at greater scale to more patients. For more information, please visit
www.allogene.com
, and follow @AllogeneTx on X (formerly Twitter) and LinkedIn.
Cautionary Note on Forward-Looking Statements for Allogene
This press release contains forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements regarding intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things Allogene’s ability to develop and deliver readily available allogeneic CAR T products for the treatment of cancer and autoimmune disease on-demand, more reliably, and at greater scale to more patients. Various factors may cause material differences between Allogene’s expectations and actual results, including risks and uncertainties related to our product candidates being based on novel technologies, which makes it difficult to predict the time and cost of product candidate development, the safety or efficacy of a product candidate, and whether a product candidate will receive regulatory approval, which could prevent or delay commercialization. These and other risks are discussed in greater detail in Allogene’s filings with the SEC, including without limitation under the heading “Risk Factors” in its most recent Annual Report on Form 10-K, Quarterly Report on Form 10-Q, and other filings that Allogene may make from time to time with the SEC. Any forward-looking statements that are made in this press release speak only as of the date of this press release. Allogene assumes no obligation to update the forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release.
Allogene Media/Investor Contact:
Christine Cassiano
EVP, Chief Corporate Affairs & Brand Strategy Officer
Christine.Cassiano@allogene.com
Citi Biopharma Back to School Conference
Wednesday, September 9
5:00 a.m. PT/8:00 a.m. ET
Any available webcasts will be posted to the Company’s website at
www.allogene.com
under the Investors tab in the News and Events section. Following a live webcast, a replay will be available on the Company’s website for approximately 30 days.
About Allogene Therapeutics
Allogene Therapeutics, with headquarters in South San Francisco, is a clinical-stage biotechnology company pioneering the development of allogeneic chimeric antigen receptor T cell (AlloCAR T) products for cancer and autoimmune disease. Led by a management team with significant experience in cell therapy, Allogene is developing a pipeline of off-the-shelf CAR T cell product candidates with the goal of delivering readily available cell therapy on-demand, more reliably, and at greater scale to more patients. For more information, please visit
www.allogene.com
, and follow @AllogeneTx on X (formerly Twitter) and LinkedIn.
Cautionary Note on Forward-Looking Statements for Allogene
This press release contains forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements regarding intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things Allogene’s ability to develop and deliver readily available allogeneic CAR T products for the treatment of cancer and autoimmune disease on-demand, more reliably, and at greater scale to more patients. Various factors may cause material differences between Allogene’s expectations and actual results, including risks and uncertainties related to our product candidates being based on novel technologies, which makes it difficult to predict the time and cost of product candidate development, the safety or efficacy of a product candidate, and whether a product candidate will receive regulatory approval, which could prevent or delay commercialization. These and other risks are discussed in greater detail in Allogene’s filings with the SEC, including without limitation under the heading “Risk Factors” in its most recent Annual Report on Form 10-K, Quarterly Report on Form 10-Q, and other filings that Allogene may make from time to time with the SEC. Any forward-looking statements that are made in this press release speak only as of the date of this press release. Allogene assumes no obligation to update the forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release.
Allogene Media/Investor Contact:
Christine Cassiano
EVP, Chief Corporate Affairs & Brand Strategy Officer
Christine.Cassiano@allogene.com
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
这条决策早于决策账本(2026-10-08 起逐条追加),没有追加记录。